Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
64Cu-NOTA-PSMA inhibitor-PEG-Cy5.5-C' dot + 89Zr-DFO-PSMA inhibitor-PEG-Cy5.5-C' dot
- Development stage
- Unknown
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
This investigational dual-tracer imaging agent consists of radiolabeled, PSMA-targeting ultrasmall silica nanoparticles (C' dots) developed by Memorial Sloan Kettering Cancer Center for the detection and image-guided surgery of prostate cancer. The platform utilizes two distinct tracers: one labeled with copper-64 (64Cu) using a NOTA chelator and another labeled with zirconium-89 (89Zr) using a DFO chelator. Both variants are conjugated with a PSMA inhibitor for specific tumor targeting, polyethylene glycol (PEG) for stability, and the near-infrared fluorescent dye Cy5.5 for intraoperative optical guidance. By combining PET/MRI imaging with real-time fluorescence, the agent aims to improve the localization of cancerous deposits and lymph node metastases during surgical resection compared to conventional imaging alone.
- Other names
- PSMA-targeting C' dotsradiolabeled PSMA-targeting C' dot tracers64Cu-NOTA-PSMA inhibitor-PEG-Cy5.5-C' dot89Zr-DFO-PSMA inhibitor-PEG-Cy5.5-C' dot
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on 64Cu-NOTA-PSMA inhibitor-PEG-Cy5.5-C' dot + 89Zr-DFO-PSMA inhibitor-PEG-Cy5.5-C' dot.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 64Cu-NOTA-PSMA inhibitor-PEG-Cy5.5-C' dot + 89Zr-DFO-PSMA inhibitor-PEG-Cy5.5-C' dot.